Katherine E. Milea
Counsel
In addition to litigation, Katherine provides patent portfolio counseling and guidance on transactional matters. She has performed due diligence for mergers and acquisitions, including ownership, freedom to operate, and patentability analyses. Her experience covers a broad range of areas and technologies, including cancer, rare genetic disorders, chronic pain, urinary symptoms, nutraceuticals, hemophilia, neutropenia, immunotherapies, and mRNA vaccines, among others.
Experience
Experience
Representative Matters
- Represented Sanofi in multiple district court litigations, Federal Circuit appeals, and an IPR against several generic companies related to Jevtana®, a chemotherapy for use in the treatment of advanced prostate cancer
- Represented Genzyme and the Regents of the University of Michigan in a Hatch-Waxman district court litigation against several generic companies related to Cerdelga®, an oral treatment for Gaucher disease
- Represented Bioverativ and Genzyme in an ITC proceeding, and a district court litigation related to Bioverativ’s patents on its monomer-dimer hybrid immunoconjugate platform technology
- Represented Sanofi in its acquisition of the clinical-stage mRNA therapeutics company Translate Bio
- Represented Grunenthal and Abiogen as petitioners in several post-grant reviews (PGRs) at the Patent Trial and Appeal Board and in related Federal Circuit appeals on patents related to the use of bisphosphonates for chronic pain
Representative Clients
- Sanofi
- Bioverativ
- Genzyme
- Grunenthal
- Abiogen
- Kite Pharma
Insights
Insights
Credentials
Credentials
Education
- J.D. cum laude Georgetown University Law Center 2015
- Articles editor, Georgetown Journal of Legal Ethics
- B.S. Neuroscience high honors University of Michigan 2012
Bar Admissions
- New York
- Michigan
- U.S. Patent and Trademark Office
Court Admissions
- U.S. Court of Appeals for the Federal Circuit
Recognition
Recognition
- The Best Lawyers in America, Ones to Watch, 2023 – 2025